SynAct Pharma AB (OSTO:SYNACT) 3-Year EBITDA Growth Rate : -48.70% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB 3-Year EBITDA Growth Rate?

SynAct Pharma AB's EBITDA per Share for the three months ended in Mar. 2024 was kr-0.72.

During the past 3 years, the average EBITDA Per Share Growth Rate was -48.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -23.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of SynAct Pharma AB was 1.40% per year. The lowest was -48.70% per year. And the median was -22.75% per year.

Competitive Comparison of SynAct Pharma AB's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, SynAct Pharma AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's 3-Year EBITDA Growth Rate falls into.

SynAct Pharma AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

SynAct Pharma AB (OSTO:SYNACT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

SynAct Pharma AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines